Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H21ClN2S.CH4O3S |
Molecular Weight | 441.007 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CN1CCN(CC1)C2CC3=CC=CC=C3SC4=CC=C(Cl)C=C24
InChI
InChIKey=XQRUOHZMMIUQSB-UHFFFAOYSA-N
InChI=1S/C19H21ClN2S.CH4O3S/c1-21-8-10-22(11-9-21)17-12-14-4-2-3-5-18(14)23-19-7-6-15(20)13-16(17)19;1-5(2,3)4/h2-7,13,17H,8-12H2,1H3;1H3,(H,2,3,4)
Molecular Formula | C19H21ClN2S |
Molecular Weight | 344.901 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | CH4O3S |
Molecular Weight | 96.106 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Clorotepine (aka octoclothepin or octoclothepine) is an antipsychotic from the tricyclic group derived from perathiepin. It was originally developed in 1965 and marketed in the Czech Republic by Spofa in or around 1971 for the treatment of schizophrenic psychosis. Clorotepine has a high affinity for the dopamine (D1, D2, D3, D4), receptors the serotonin 5-HT (2A, 2B, 2C, 6, 7) receptors, the alpha-adrenergic receptors (1A, 1B, 1D), and the histamine H1 receptors. In most instances, it acts as an antagonist (or inverse agonist). Clorotepine will also block the reuptake of norepinephrine by inhibiting the norepinephrine transporter.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P28223 Gene ID: 3356.0 Gene Symbol: HTR2A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1676758 |
0.57 nM [IC50] | ||
Target ID: P35348|||B0ZBD9|||Q6RUJ8 Gene ID: 148.0 Gene Symbol: ADRA1A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1676758 |
0.18 nM [IC50] | ||
Target ID: P21728 Gene ID: 1812.0 Gene Symbol: DRD1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1676758 |
2.2 nM [IC50] | ||
Target ID: P14416 Gene ID: 1813.0 Gene Symbol: DRD2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1676758 |
2.4 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Clotepin Approved UseUnknown |
|||
Primary | Clotepin Approved UseUnknown |
|||
Primary | Clotepin Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6231812
Clorotepin is provided in doses up to 2 mg.
Route of Administration:
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:17:21 GMT 2023
by
admin
on
Sat Dec 16 09:17:21 GMT 2023
|
Record UNII |
KLU0VHS3Y4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID00962538
Created by
admin on Sat Dec 16 09:17:21 GMT 2023 , Edited by admin on Sat Dec 16 09:17:21 GMT 2023
|
PRIMARY | |||
|
198244
Created by
admin on Sat Dec 16 09:17:21 GMT 2023 , Edited by admin on Sat Dec 16 09:17:21 GMT 2023
|
PRIMARY | |||
|
42505-79-3
Created by
admin on Sat Dec 16 09:17:21 GMT 2023 , Edited by admin on Sat Dec 16 09:17:21 GMT 2023
|
PRIMARY | |||
|
KLU0VHS3Y4
Created by
admin on Sat Dec 16 09:17:21 GMT 2023 , Edited by admin on Sat Dec 16 09:17:21 GMT 2023
|
PRIMARY | |||
|
255-855-4
Created by
admin on Sat Dec 16 09:17:21 GMT 2023 , Edited by admin on Sat Dec 16 09:17:21 GMT 2023
|
PRIMARY |